Delivery Order SPE2DB22D3301-SPE2DB24FY1YB
Award Date 3/5/24
Potential Completion Date 3/6/24
Potential Value $9.7K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order worth $1,497.82 to Amerisourcebergen Drug Corp, a wholly-owned subsidiary of Amerisourcebergen Corporation, for the supply of RABAVERT rabies vaccine with diluents. This delivery order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA, which serves as the primary contract vehicle for the company to deliver pharmaceutical...
- The Defense Logistics Agency (DLA) Troop Support Medical has awarded a $2,895.45 firm fixed price delivery order to Amerisourcebergen Drug Corp, a for-profit pharmaceutical distribution company, to provide RABAVERT rabies vaccine with diluents. The order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA, which serves as the primary vehicle for the company to deliver pharmaceuticals and medical supplies...
- The Defense Logistics Agency (DLA) awarded a $34,277.94 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RABAVERT rabies vaccine with diluents. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. The IDC enables the DLA to efficiently procure a...
- The U.S. Defense Logistics Agency (DLA) awarded a $19,970.00 firm fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RABAVERT rabies vaccine with diluents. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to...
- The Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp., a subsidiary of Amerisourcebergen Corporation, a $1,930.30 firm fixed price delivery order contract to provide RABAVERT rabies vaccine with diluents. This delivery order is part of an Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp. with DLA, which has a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $2,895.45 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide RABAVERT rabies vaccine with diluents. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, valued at up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary contract vehicle for Amerisourcebergen to deliver...
- The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RABAVERT rabies vaccine with diluents. The contract, valued at $5,790.90, has an ultimate completion date of October 11, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which enables the agency to efficiently procure...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide RABAVERT rabies vaccine with diluents. The $38,606.00 delivery order has a completion date of February 27, 2024. Amerisourcebergen Drug Corp, a for-profit organization, is the prime contractor on an indefinite delivery contract (IDC) valued up to $999,999,999.00 with DLA to deliver pharmaceutical products and medical...
- The U.S. government's Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide RABAVERT rabies vaccine with diluents. The award, valued at $35,517.52, has an ultimate completion date of April 1, 2024. This order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen Drug Corp holds with DLA to deliver pharmaceutical...
- The U.S. Defense Logistics Agency (DLA) awarded a $27,106.80 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to supply RABAVERT rabies vaccine with diluents. This contract has an ultimate completion date of August 23, 2024 and was not set aside for any specific business category. Amerisourcebergen holds several Indefinite Delivery Contracts (IDCs) with DLA and other federal agencies, valued up to $999,999,999 and $750,000 respectively,...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB24FY1YBDelivery Order
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $9,651.50 to Amerisourcebergen Drug Corp, a for-profit pharmaceutical distribution company, for the supply of RABAVERT rabies vaccine with diluents. This delivery order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA to provide a comprehensive range of pharmaceutical products and medical supplies to support military treatment programs and facilities worldwide. The contract has a performance period through December 31, 2025 and does not include any set-aside designations.
Generated 6/4/24, 10:03 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.7k | 3/5/24 |